Catherine Novack
Stock Analyst at Jones Trading
(1.40)
# 3,593
Out of 5,127 analysts
23
Total ratings
26.32%
Success rate
-0.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Catherine Novack
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SEPN Septerna | Initiates: Buy | $43 | $26.59 | +61.71% | 1 | Dec 23, 2025 | |
| KRRO Korro Bio | Downgrades: Hold | n/a | $12.74 | - | 2 | Nov 14, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Buy | $33 | $13.48 | +144.81% | 1 | Oct 1, 2025 | |
| DYN Dyne Therapeutics | Initiates: Buy | $30 | $16.99 | +76.57% | 1 | Jun 26, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $40 → $29 | $25.19 | +15.13% | 2 | Jun 25, 2025 | |
| FEMY Femasys | Maintains: Buy | $10 → $6 | $0.53 | +1,029.52% | 2 | May 13, 2025 | |
| RLYB Rallybio | Downgrades: Hold | n/a | $4.70 | - | 1 | Apr 15, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Buy | $45 | $77.82 | -42.17% | 1 | Mar 25, 2025 | |
| PRQR ProQR Therapeutics | Initiates: Buy | $11 | $1.47 | +648.30% | 1 | Feb 12, 2025 | |
| EQ Equillium | Downgrades: Hold | n/a | $1.50 | - | 1 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $16 | $13.67 | +17.04% | 2 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $3.39 | +312.98% | 1 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $13 | $1.71 | +660.23% | 2 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $3.13 | +219.49% | 1 | Apr 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $0.65 | +3,270.10% | 1 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $6.15 | - | 2 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $160 | $0.59 | +27,157.24% | 1 | Jul 21, 2023 |
Septerna
Dec 23, 2025
Initiates: Buy
Price Target: $43
Current: $26.59
Upside: +61.71%
Korro Bio
Nov 14, 2025
Downgrades: Hold
Price Target: n/a
Current: $12.74
Upside: -
Aardvark Therapeutics
Oct 1, 2025
Initiates: Buy
Price Target: $33
Current: $13.48
Upside: +144.81%
Dyne Therapeutics
Jun 26, 2025
Initiates: Buy
Price Target: $30
Current: $16.99
Upside: +76.57%
Capricor Therapeutics
Jun 25, 2025
Maintains: Buy
Price Target: $40 → $29
Current: $25.19
Upside: +15.13%
Femasys
May 13, 2025
Maintains: Buy
Price Target: $10 → $6
Current: $0.53
Upside: +1,029.52%
Rallybio
Apr 15, 2025
Downgrades: Hold
Price Target: n/a
Current: $4.70
Upside: -
Palvella Therapeutics
Mar 25, 2025
Initiates: Buy
Price Target: $45
Current: $77.82
Upside: -42.17%
ProQR Therapeutics
Feb 12, 2025
Initiates: Buy
Price Target: $11
Current: $1.47
Upside: +648.30%
Equillium
Nov 1, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.50
Upside: -
Sep 25, 2024
Maintains: Buy
Price Target: $12 → $16
Current: $13.67
Upside: +17.04%
Sep 12, 2024
Initiates: Buy
Price Target: $14
Current: $3.39
Upside: +312.98%
Aug 16, 2024
Maintains: Buy
Price Target: $5 → $13
Current: $1.71
Upside: +660.23%
Apr 18, 2024
Initiates: Buy
Price Target: $10
Current: $3.13
Upside: +219.49%
Feb 16, 2024
Initiates: Buy
Price Target: $22
Current: $0.65
Upside: +3,270.10%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $6.15
Upside: -
Jul 21, 2023
Initiates: Buy
Price Target: $160
Current: $0.59
Upside: +27,157.24%